参考文献/References:
[1]王宁,刘硕,杨雷,等.2018全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2019,5(1):87-97. [2]Gettinger S,Horn L,Jackman D,et al.Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer:Results From the CA209-003 Study[J].Journal of Clinical Oncology,2018,36(17):1675-1684. [3]刘丽娅,朱颖,涂长玲,等.小分子抗血管生成药物在非小细胞肺癌中的研究进展[J].现代肿瘤医学,2020,28(4):663-667. [4]韩宝惠,李凯,周彩存,等.晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2019版)[J].中国肺癌杂志,2019,22(7):401-412. [5]徐升,徐经世.国医大师徐经世治疗肺癌学术经验[J].山东中医杂志,2018,37(4):319-321. [6]张艳.EGFR-TKI联合化疗一线治疗EGFR突变阳性NSCLC的随机对照研究[D].山东大学,2017. [7]霍飞,张蕊.1996-2015年吸烟与肺癌国际研究状况文献计量学分析[J].中国慢性病预防与控制,2016,24(6):477-478. [8]陈文杰,李高峰.非小细胞肺癌的分子靶向治疗研究进展[J]. 现代肿瘤医学,2017,25(12):1994-1996. [9]李蓉,谭小武.安罗替尼治疗晚期非小细胞肺癌的疗效及安全性评估[J].现代医药卫生,2019,35(18):2815-2817. [10]冯久桓,秦叔逵,王琳.甲磺酸阿帕替尼的研究现状与进展[J].临床肿瘤学杂志,2017,22(4):345-356. [11]王睿晴,张艳华.抗肿瘤分子靶向药物安罗替尼的临床研究进展[J].中国新药杂志,2018,27(23):2770-2774. [12]沈娟,陈雪琴,马胜林.安罗替尼抗肿瘤作用研究进展[J].浙江医学,2019,41(23):2556-2560. [13]王俊,冉凤鸣,金兵.安罗替尼治疗恶性肿瘤的临床研究进展[J].中国肿瘤,2019,28(5):359-366. [14]Baohui H,Kai L,Yizhuo Z,et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer:a multicentre,randomised phase II trial(ALTER0302)[J].British Journal of Cancer,2018,118(5):654-661. [15]Han B,Li K,Wang Q,et al.Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer:The ALTER 0303 Phase 3 Randomized Clinical Trial[J].JAMA Oncology,2018,4(11):1569-1575. [16]韩骐蔓,侯和磊,张晓春.国产创新药安罗替尼抗肿瘤治疗的研究进展[J].中国新药与临床杂志,2020,39(2):65-70. [17]李崇慧.徐经世老中医治疗恶性消化道肿瘤经验[J].中国中医急症,2008(6):800-832. [18]杨忠光,梁鑫,赵远桥.沙参麦冬汤联合化疗对气阴两虚型肺癌患者免疫功能及炎性反应的影响[J].中国实验方剂学杂志,2017,23(16):158-163. [19]李海舟.沙参麦冬汤对中晚期非小细胞肺癌患者免疫功能及生活质量的影响[J].吉林医药学院学报,2019,40(3):197-198.
相似文献/References:
[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Medical Information,2018,31(02):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Medical Information,2018,31(02):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的
表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Medical Information,2018,31(02):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Medical Information,2018,31(02):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Medical Information,2018,31(02):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[6]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Medical Information,2018,31(02):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[7]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(02):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[8]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2019,32(02):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[9]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Medical Information,2019,32(02):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
[10]杨珑静,马洪波,张献全.抗血管生成药物在非小细胞肺癌中的应用及研究进展[J].医学信息,2019,32(08):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]
YANG Long-jing,MA Hong-bo,ZHANG Xian-quan.Application and Research Progress of Anti-angiogenic Drugs in Non-small Cell Lung Cancer[J].Medical Information,2019,32(02):58.[doi:10.3969/j.issn.1006-1959.2019.08.018]